Clinical Trial Update: Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update reports the efficacy and safety of linagliptin (BI-1356) in Black/African American patients with type 2 diabetes mellitus, inclu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Linagliptin (BI-1356) (linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2012-10-26